[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"pcos\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:pcos":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,15,0,[8,48,76,100,128,155,180,207,230,257,283,314,344,367,393],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":29,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":4},"100639095","observational-study-on-the-causal-architecture-of-polycystic-ovary-syndrome-pcos-100639095",false,"NCT07623551","Observational Study on the Causal Architecture of Polycystic Ovary Syndrome (PCOS)","An Observational Data Collection Study to Characterize the Hormonal, Metabolic, and Clinical Architecture of Polycystic Ovary Syndrome in Women Aged 18 to 45: A Global Recruitment Initiative","Inclusion Criteria:\n\n* Female\n* Aged 18 to 45 years\n* Diagnosed with Polycystic Ovary Syndrome (PCOS) by a licensed healthcare provider\n* Willing to voluntarily share existing lab results and clinical history\n* Able to provide informed consent\n\nExclusion Criteria:\n\n* Under 18 years of age\n* Over 45 years of age\n* No confirmed PCOS diagnosis from a licensed healthcare provider\n* Unable or unwilling to provide informed consent","FEMALE","18 Years","45 Years",{"count":20,"type":21},100,"ESTIMATED","OBSERVATIONAL","The goal of this observational study is to learn about the causal architecture of Polycystic Ovary Syndrome (PCOS) in women aged 18 to 45. The main questions it aims to answer are:\n\nWhat does the hormonal, metabolic, and clinical architecture of PCOS look like across a diverse global population? Can the causal architecture of PCOS be reconstructed from existing lab results and clinical data? Are there distinct architectural patterns across different groups of women with PCOS? Participants who have been diagnosed with PCOS by a healthcare provider will complete an online questionnaire about their diagnosis, symptoms, clinical history, current treatment, and existing lab results. Participants will also be asked to submit copies of their most recent blood work and lab results. No intervention or treatment is involved. All data is de-identified.",[25,26,27,28],"Polycystic Ovary Syndrome","Polycystic Ovary Syndrome (PCOS)","PCOS","PCOS (Polycystic Ovary Syndrome)",[27,25,30,31,32,33,34,35],"Women's Health","Endocrine","Hormonal","Metabolic","Observational Study","Causal Architecture","NOT_YET_RECRUITING","2026-05-28",{"date":39,"type":40},"2026-06-03","ACTUAL",{"date":42,"type":21},"2026-06",{"date":44,"type":21},"2026-07",{"name":46,"class":47},"AnnieGuard Corp.","INDUSTRY",{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":4,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":55,"enrollmentInfo":56,"targetDuration":4,"studyType":58,"phases":59,"briefSummary":61,"conditions":62,"keywords":4,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":75},"100514506","phase-1-bicalutamide-therapy-in-young-women-with-nafld-and-pcos-100514506","NCT05979389","Bicalutamide Therapy in Young Women With NAFLD and PCOS","Pilot Trial of Bicalutamide Versus Placebo in Reproductive-Aged Women With Nonalcoholic Fatty Liver Disease (NAFLD) and Polycystic Ovary Syndrome (PCOS)","Inclusion Criteria:\n\n* Women aged 18-42 years with hyperandrogenic PCOS\n* NASH identified on liver biopsy or probable NASH on transient elastography- controlled attenuation parameter (TE-CAP) with cutoffs defined as CAP score ≥270 decibel\u002Fm and TE score \\> 7.0 kPA or alanine aminotransferase ≥40 U\u002FL).\n\nExclusion Criteria:\n\n* Uncontrolled diabetes\n* Alcohol consumption \\>2 drinks per day for at least 3 consecutive months over the previous 5 years\n* Other chronic liver disease (i.e. hepatitis B virus, hepatitis C virus, autoimmune hepatitis) or cirrhosis from any cause\n* Recent or planned upcoming weight reduction surgery within five years of diagnosis of biopsy-confirmed NASH\n* HIV infection\n* Drugs associated with fatty liver (i.e. amiodarone, methotrexate, systemic glucocorticoids, tamoxifen, anabolic steroids, valproic acid) for more than 4 weeks prior to baseline or during study\n* Recent, current, or planned upcoming pregnancy or current perimenopausal status\n* Renal impairment (glomerular filtration rate \\\u003C45 ml\u002Fmin\u002F1.73m or potassium levels \\> 5.0 mmol\u002FL)\n* Androgen receptor antagonist use (i.e. spironolactone or flutamide) for more than 3 months within one year prior to baseline","42 Years",{"count":57,"type":21},50,"INTERVENTIONAL",[60],"PHASE1","Nonalcoholic steatohepatitis (NASH), or fat-related liver inflammation and scarring is projected to be the leading cause of cirrhosis in the United States (U.S.) within the next few years. Women are at disproportionate risk for NASH, with approximately 15 million U.S. women affected. There is an urgent need to understand risk factors for NASH and its progression in women, and sex hormones may provide a missing link. This study will study the contribution of androgens to liver injury and progression in PCOS and mechanistic role of dysregulated lipid metabolism and visceral adiposity in this process. Such findings will provide the rationale for future efficacy studies evaluating selective androgen receptor (AR) antagonism for NASH in PCOS, or alternatively, the need to directly target visceral adiposity or lipid-specific pathways as part of a precision medicine approach to halt fibrosis progression in the nearly 5 million young women with PCOS and NAFLD in the U.S., who remain at increased risk for early onset and progressive liver disease.",[63,27],"NAFLD","RECRUITING","2026-05-26",{"date":67,"type":40},"2026-05-29",{"date":69,"type":40},"2024-02-14",{"date":71,"type":21},"2028-08",{"name":73,"class":74},"University of California, San Francisco","OTHER",1,{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":4,"eligibilityCriteria":82,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":55,"enrollmentInfo":83,"targetDuration":85,"studyType":22,"phases":4,"briefSummary":86,"conditions":87,"keywords":89,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":99},"100525632","androgens-and-nafld-longitudinal-cohort-study-100525632","NCT06124261","Androgens and NAFLD Longitudinal Cohort Study","Androgens and Nonalcoholic Fatty Liver Disease (NAFLD) In Reproductive-Aged Women With and Without Polycystic Ovary Syndrome (PCOS)","Inclusion Criteria:\n\n* Metabolic associated steatohepatitis (MASH) (formerly NASH)\n* PCOS\n* Non-PCOS\n\nExclusion Criteria:\n\n* High levels of alcohol use (more than 7 drinks a week)\n* Current pregnancy\n* Other causes of hepatic steatosis\n* Weight loss of more than 10% body weight in the last 6 months",{"count":84,"type":21},150,"3 Years","The researchers want to learn how androgens, a type of sex hormone, might affect nonalcoholic fatty liver (NAFLD) in young women over time. NAFLD happens when fat builds up in the liver which can cause damage to the liver such as inflammation or scarring.\n\nYoung women with a condition called polycystic ovary syndrome (PCOS) have a high risk for NAFLD, and they often have high androgen levels too. So the researchers are recruiting young women with PCOS as well as those without PCOS, and will compare changes in NAFLD over time between young women with and without PCOS.\n\nThis study is funded by the National Institutes of Health",[27,63,88],"NASH",[90],"Androgen","2026-04-09",{"date":93,"type":40},"2026-04-13",{"date":95,"type":40},"2024-01-22",{"date":97,"type":21},"2028-12",{"name":73,"class":74},2,{"id":101,"slug":102,"hasResults":11,"nctId":103,"briefTitle":104,"officialTitle":105,"acronym":4,"eligibilityCriteria":106,"healthyVolunteers":11,"sex":16,"minAge":107,"maxAge":108,"enrollmentInfo":109,"targetDuration":4,"studyType":58,"phases":111,"briefSummary":113,"conditions":114,"keywords":117,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":120,"lastUpdatePostDateStruct":121,"startDateStruct":123,"completionDateStruct":125,"leadSponsor":126,"locationsCount":75},"100584326","pims-vs-pgt-a-in-infertile-pcos-patients-100584326","NCT06887881","PIMS vs PGT-A in Infertile PCOS Patients","Clinical Use of Preimplantation DNA Methylation Screening (PIMS) and Preimplantation Genetics Screening (PGT-A) in Infertile PCOS Patients-A Multicenter, Prospective Randomized Non-inferior Clinical Trial","Inclusion Criteria:\n\n1. Women aged between 20 and 40 years diagnosed with PCOS according to international evidence-based guidline for assessment and management of policystic ovarian syndrome 2018.\n2. Women who plan to undergo the 1st\u002F2nd IVF\u002FICSI\u002FPGT-A treatment cycle.\n3. Women who obtain 2 or more blastocysts that have morphological score of 4BC\u002F4CB or better on Day 5of embryo culture.\n4. Culture all the cleavage stage embryos into blastocysts, conduct biopsy on all the blastocysts, and cryopreserve each blastocyst as a single embryo\n5. Agree to the thawing and transfer of a single blastocyst.\n6. Sign the informed consent form.\n\nExclusion Criteria:\n\n1. Women with a uterine cavity abnormality, such as a uterine congenital malformation (uterus unicornate, bicornate, or duplex); untreated uterine septum, submucous myoma, or endometrial polyp(s); or with history of intrauterine adhesions.\n2. Women who are indicated and planned to undergo preimplantation genetic testing for structural rearrangements (PGT-SR) or preimplantation genetic testing for monogenic (PGT-M).\n3. Women who use donated oocytes or sperm to achieve pregnancy.\n4. Women with contraindication for assisted reproductive technology or for pregnancy, such as undiagnosed liver disease or dysfunction (based on serum liver enzyme testing); renal disease or abnormal serum renal function; significant anemia; history of deep venous thrombosis, pulmonary embolus, or cerebrovascular accident; uncontrolled hypertension, known symptomatic heart disease; history of or suspected carcinoma including including cervical carcinoma, endometrial carcinoma, or breast carcinoma; undiagnosed vaginal bleeding and so on.\n5. Untreated hydrosalpinx according to ultrasonography test.","20 Years","40 Years",{"count":110,"type":21},766,[112],"NA","This experiment has become a serious issue for two reasons: DNA methylation plays an important role during embryogenesis, global abnormal methylome reprogramming often occurs in human embryos, and DNA methylome pattern is associated with live birth rate. The endocrine metabolic disorders of polycystic ovarian syndrome (PCOS) patients may affect the epigenetic status of embryos and lead to the increase of early pregnancy loss rate in PCOS patients. However, there is still no technology using DNA methylome as an indicator in preimplantation embryo screening in PCOS patients. Our recent study showed that using Pre-implantation Methylation Screening (PIMS) can select embryos with better methylation state and euploid chromosomes. The efficiency of PIMS in PCOS patients needs further validation through randomized controlled clinical trial.\n\nThe purpose of the study is to compare whether the two groups of PCOS patients who selected embryos using PIMS and selected embryos using \"PGT-A + morphology\"had any difference in early pregnancy loss rate. This study aims to explore whether PIMS can be used as another embryo evaluation method besides \"PGT-A+morphology\" to screen good developmental potential embryos in patients with PCOS. Investigators need to clarify whether a better embryo evaluation system can be established through PIMS technology during assisted reproductive treatment for infertile PCOS couples and provide credible and effective evidence-based medical evidence for the application of PMIS technology in the field of reproductive medicine.",[115,27,116],"PGT-A","PIMS",[116,27,115,118,119],"cumulative live birth rate","early pregnancy loss rate","2026-03-29",{"date":122,"type":40},"2026-04-02",{"date":124,"type":40},"2025-06-12",{"date":97,"type":21},{"name":127,"class":74},"First Affiliated Hospital, Sun Yat-Sen University",{"id":129,"slug":130,"hasResults":11,"nctId":131,"briefTitle":132,"officialTitle":133,"acronym":4,"eligibilityCriteria":134,"healthyVolunteers":135,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":136,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":138,"conditions":139,"keywords":141,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":146,"lastUpdatePostDateStruct":147,"startDateStruct":149,"completionDateStruct":151,"leadSponsor":153,"locationsCount":75},"100577036","adipokines-in-polycystic-ovary-syndrome-100577036","NCT06793072","Adipokines in Polycystic Ovary Syndrome","Assessment of Adipokine Concentrations and Their Association With the Metabolic Profile of Women With PCOS","Inclusion Criteria:\n\n* Age 18-45\n\nExclusion Criteria:\n\n* previous removal of at least one ovary\n* treated diabetes of any type\n* diagnosed and treated metabolic diseases\n* diagnosed and treated autoimmune diseases\n* diagnosed and treated autoinflammatory diseases(Edited)Restore original",true,{"count":137,"type":21},300,"The aim of the study is to compare the concentrations of leptin, resistin, and omentin-1 in women across three research groups: those with polycystic ovary syndrome without insulin resistance, those with polycystic ovary syndrome with insulin resistance, and women without polycystic ovary syndrome.",[27,140],"Reproductive Age",[142,143,144,145],"insulin resistance","polycystic ovary syndrome","metabolic syndrome","adipokines","2026-03-17",{"date":148,"type":40},"2026-03-18",{"date":150,"type":40},"2025-01-20",{"date":152,"type":21},"2027-12-31",{"name":154,"class":74},"Jagiellonian University",{"id":156,"slug":157,"hasResults":11,"nctId":158,"briefTitle":159,"officialTitle":160,"acronym":161,"eligibilityCriteria":162,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":163,"enrollmentInfo":164,"targetDuration":4,"studyType":58,"phases":166,"briefSummary":167,"conditions":168,"keywords":169,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":171,"lastUpdatePostDateStruct":172,"startDateStruct":174,"completionDateStruct":176,"leadSponsor":178,"locationsCount":75},"100612617","cabergoline--letrozole-versus-letrozole-in-ovulation-induction-in-pcos-100612617","NCT07255911","Cabergoline & Letrozole Versus Letrozole in Ovulation Induction in PCOS","Cabergoline and Letrozole Compared to Letrozole Alone for Ovulation Induction in Infertile Women With Polycystic Ovary Syndrome","PCOS OID","Inclusion Criteria:\n\n1. PCOS patients diagnosed according to Rotterdam criteria.\n2. Age: 18-35 years.\n3. Primary or secondary subfertility.\n4. Selected for ovulation induction.\n\nExclusion Criteria:\n\n1. Women suffered from PCOS like symptom ex. Late onset congenital adrenal hyperplasia, Cushing syndrome.\n2. Serum prolactin (more than 50 ng\u002Fml) (Kyritsi et al., 2018).\n3. Male factor infertility.\n4. Women with other infertility factors (endometriosis, PID,uterine \\& tubal causes of infertility).\n5. Uncontrolled Medical disease (DM, HTN, kidney disease, liver disease).\n6. History of hypersensitivity to cabergoline \\& letrozole.\n7. Thyroid dysfunction ( serum TSH ≥5mIU\u002FL)\n8. BMI:\\\u003C 18.5 kg\u002Fm2 and ≥30 kg\u002Fm2.\n9. Patients on metformin therapy.\n10. Patient on antiemetic like Domperidone metoclopramide, antipsychotic drug like haloperidol and risperidone, tricyclic antidepressant like amitriptyline, clomipramine, antihypertensive like verapamil, methyldopa, reserpine.","35 Years",{"count":165,"type":21},72,[112],"Does combined Cabergoline and letrozole increase ovulation rate What medical problems do participants have when taking drug Cabergoline and Letrozole ? Researchers will compare drug combination of Cabergoline and letrozole to letrozole alone to see combined cabergoline and letrozole works better as ovulation induction.\n\nParticipants will:\n\nexperimental group will receive Cabergoline and Letrozole comparator group will receive letrozole alone TVS Monitoring will be done for 3 cycle for ovarian response",[27],[170],"ovulation induction by Cabergoline","2025-12-09",{"date":173,"type":40},"2025-12-16",{"date":175,"type":40},"2025-02-07",{"date":177,"type":21},"2026-06-30",{"name":179,"class":74},"Mst.Sumyara Khatun",{"id":181,"slug":182,"hasResults":11,"nctId":183,"briefTitle":184,"officialTitle":185,"acronym":4,"eligibilityCriteria":186,"healthyVolunteers":11,"sex":16,"minAge":187,"maxAge":18,"enrollmentInfo":188,"targetDuration":4,"studyType":58,"phases":190,"briefSummary":191,"conditions":192,"keywords":4,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":197,"lastUpdatePostDateStruct":198,"startDateStruct":200,"completionDateStruct":202,"leadSponsor":204,"locationsCount":206},"100548735","phase-1-fish-oil-metformin-and-heart-health-in-pcos-100548735","NCT06424860","Fish Oil, Metformin and Heart Health in PCOS","Dietary Fish Oil and Metformin Intervention for Heart Health in PCOS","Inclusion Criteria:\n\n* diagnosis of PCOS\n* overweight-obese (BMI \\>25 kg\u002Fm2)\n* elevated fasting plasma TG (\\>150 mg\u002FdL)\n* and\u002For apoB48-remnant cholesterol lipoproteins (\\>20 ug\u002Fml)\n* impaired insulin sensitivity (glucose 100-125 mg\u002FdL and\u002For insulin \\>15 (uM\u002Fml), and may be diagnosed with T2D (blood glucose \\>126 mg\u002FdL).\n\nExclusion Criteria:\n\n-pregnancy, lactation","25 Years",{"count":189,"type":21},146,[60],"Women with Polycystic Ovary Syndrome (PCOS) have high testosterone levels which is associated with altered insulin-glucose metabolism and an adverse blood lipid profile, predisposing them to the development of Type II Diabetes and Cardiovascular Disease (CVD). This study will investigate the use of dietary fish oil supplementation as a safe and effective intervention, and as an adjunct therapy to standard of care treatment with metformin to improve heart health, blood lipids and insulin-glucose metabolism in women with PCOS, and those with PCOS and Type 2 Diabetes.",[27,193,194,195,196],"Cardiovascular Disease","Atherosclerotic Cardiovascular Disease","Atherosclerotic Plaque","Cardiac Hypertrophy","2025-12-04",{"date":199,"type":40},"2025-12-12",{"date":201,"type":40},"2025-11-01",{"date":203,"type":21},"2027-12-30",{"name":205,"class":74},"University of Alberta",3,{"id":208,"slug":209,"hasResults":11,"nctId":210,"briefTitle":211,"officialTitle":212,"acronym":4,"eligibilityCriteria":213,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":214,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":216,"conditions":217,"keywords":4,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":221,"lastUpdatePostDateStruct":222,"startDateStruct":224,"completionDateStruct":226,"leadSponsor":228,"locationsCount":75},"100584447","cardiovascular-and-endothelial-markers-during-ogtt-before-and-at-six-and-twelve-months-post-treatment-in-women-with-pcos-100584447","NCT06889454","Cardiovascular and Endothelial Markers During OGTT Before and at Six and Twelve Months Post-treatment in Women With PCOS","The Effect of Different Treatment Options on Markers of Vascular, Myocardial and Endothelial Function in Women With Polycystic Ovary Syndrome and the Association With Metabolic and Hormonal Abnormalities of the Syndrome","Inclusion Criteria:\n\n1. Age \\> 16 years old\n2. Diagonis of PCOS according to Rotterdam criteria: presence of two of the three of the following:\n\n   * Clinical or biochemical hyperandrogenism\n   * Anovulation or oligo-ovulation\n   * Polycystic ovarian morphology (PCOM)\n3. Absence of treatment for PCOS the last six months\n4. Patients who have the ability to understand and sign the consent form.\n\nExclusion Criteria:\n\n1. Disorders with clinical presentation similar to PCOS: thyroid disease, hyperprolactinemia, and non-classic congenital adrenal hyperplasia (primarily 21-hydroxylase deficiency by serum 17-hydroxyprogesterone \\[17-OHP\\]), Cushing syndrome, acromegaly\n2. Treatment with contraceptive or metformin\n3. Type 2 diabetes mellitus\n4. Treatment for diabetes\n5. Pregnancy\n6. Lactation\n7. Malignancy",{"count":215,"type":21},120,"The aim of the present study is to investigate a) the presence of subclinical markers of vascular, myocardial and endothelial function in women with PCOS b) the acute alterations in these markers during the oral glucose tolerance test (OGTT) c) the impact of potential treatment interventions in these markers.",[27,218,219,220],"Hyperinsulinism","Hyperandrogenism","Metabolic Syndrome","2025-11-15",{"date":223,"type":40},"2025-11-19",{"date":225,"type":40},"2024-02-01",{"date":227,"type":21},"2026-02-01",{"name":229,"class":74},"Attikon Hospital",{"id":231,"slug":232,"hasResults":11,"nctId":233,"briefTitle":234,"officialTitle":234,"acronym":235,"eligibilityCriteria":236,"healthyVolunteers":11,"sex":16,"minAge":107,"maxAge":108,"enrollmentInfo":237,"targetDuration":4,"studyType":58,"phases":239,"briefSummary":241,"conditions":242,"keywords":245,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":249,"lastUpdatePostDateStruct":250,"startDateStruct":252,"completionDateStruct":253,"leadSponsor":255,"locationsCount":206},"100573163","phase-4-liraglutide-treatment-in-obese-infertile-pcos-women-100573163","NCT06742710","Liraglutide Treatment in Obese Infertile PCOS Women","LITOP","Inclusion Criteria:\n\n* Women with polycystic ovary syndrome (PCOS) who meet the Rotterdam diagnostic criteria.\n* Aged 20-40 years;\n* 25 kg\u002Fm2 ≤ BMI ≤ 35 kg\u002Fm2;\n* Have not used any anti-diabetes or weight-loss medications (metformin excluded) within the past 3 months;\n* Have at least 1 transplantable frozen embryo available at the research center;\n* Able to follow the study's contraceptive requirements.\n\nExclusion Criteria:\n\n* Diabetic ketoacidosis or other acute complications of diabetes;\n* HbA1c ≥ 9.0% before enrollment;\n* Using drugs that affect appetite or nutrient absorption within the past 2 months (metformin excluded);\n* Uncontrolled hyperthyroidism or hypothyroidism, hypertension, systemic autoimmune diseases, etc. that may affect pregnancy and fetal development;\n* 17 hydroxyprogesterone in follicualr phase \\> 2.0 ng\u002Fml;\n* Serious cardiovascular, digestive, liver, or kidney diseases, HBsAg-positive chronic hepatitis B, active pulmonary tuberculosis, or AIDS, etc. that are infectious or hereditary diseases;\n* Any psychiatric or psychological disorders requiring drug treatment;\n* Poor pregnancy and delivery history: recurrent failed implantations ≥3 times, spontaneous abortions ≥2 times; history of stillbirth, dystocia, or birth defects; previous pregnancies with preeclampsia, eclampsia, or HELLP syndrome;\n* Uncontrolled metabolic, autoimmune, or hereditary disease in the husband;\n* A contraindication or relative contraindication to using GLP-1 receptor agonists (history of medullary thyroid carcinoma or family history of medullary thyroid carcinoma, acute cholecystitis or pancreatitis in the acute phase or history of previous attacks, GLP-1 receptor agonist allergy, etc.);\n* Failure to comply with the contraceptive requirements of the study design;\n* Failure to take medication regularly and follow up;\n* Current smokers, drug addicts, alcoholics, or individuals with substance abuse;\n* Participants who have participated in any clinical trial within the past 3 months prior to screening;\n* Individuals with other conditions deemed unsuitable for participation in this clinical trial by the investigator;",{"count":238,"type":21},890,[240],"PHASE4","Liraglutide, a hypoglycemic drug, can reduce weight and improve insulin resistance while stabilizing blood glucose metabolism without increasing the risk of hypoglycemia, and has been approved by the State Food and Drug Administration of China and the US Food and Drug Administration for the treatment of obesity. Polycystic ovary syndrome (PCOS) is the main cause of female anovulatory infertility, and it is also a high-risk group of obesity. Previous studies have suggested that liraglutide improves glucose metabolism, body weight, and inflammation levels in obese women with PCOS, and improves sex hormone profiles and menstrual cycles, possibly contributing to increased fertility.\n\nTherefore, this project intends to test the following hypothesis through a large sample randomized controlled trial in obese and infertile PCOS women who are assisted by in vitro fertilization-frozen embryo transfer (IVF-FET), using liraglutide before transplantation to reduce weight can improve the live birth rate of assisted reproduction.",[27,243,244],"Obesity","Infertility",[143,246,247,248],"liraglutide","infertile","obesity","2025-05-22",{"date":251,"type":40},"2025-05-29",{"date":249,"type":40},{"date":254,"type":21},"2029-12-31",{"name":256,"class":74},"Peking University Third Hospital",{"id":258,"slug":259,"hasResults":11,"nctId":260,"briefTitle":261,"officialTitle":262,"acronym":4,"eligibilityCriteria":263,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":264,"targetDuration":4,"studyType":58,"phases":266,"briefSummary":267,"conditions":268,"keywords":269,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":274,"lastUpdatePostDateStruct":275,"startDateStruct":277,"completionDateStruct":279,"leadSponsor":281,"locationsCount":99},"100527112","phase-1-safety-of-cultured-allogeneic-adult-umbilical-cord-derived-mesenchymal-stem-cells-for-pcos-100527112","NCT06143527","Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cells for PCOS","Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cells for the Treatment of Polycystic Ovary Syndrome","Inclusion Criteria:\n\n• Ultrasound documented poly cystic ovary syndrome\n\nExclusion Criteria:\n\n* Active infection\n* Active cancer\n* Chronic multisystem organ failure\n* Pregnancy\n* Clinically significant abnormalities on pre-treatment laboratory evaluation\n* Medical condition that would (based on the opinion of the investigator) compromise patient's safety\n* Continued drug abuse\n* Previous organ transplant\n* Hypersensitivity to sulfur\n* Inability to supply proper informed consent",{"count":265,"type":21},20,[60],"This trial will study the safety and efficacy of cultured allogeneic adult umbilical cord derived mesenchymal stem cells delivered intravenously for the treatment of Polycystic Ovary Syndrome.",[26,25,27],[26,25,27,270,271,272,273],"Stem Cell","Stem Cells","Mesenchymal Stem Cells","Umbilical Cord Derived Mesenchymal Stem Cells","2025-04-04",{"date":276,"type":40},"2025-04-08",{"date":278,"type":40},"2023-11-16",{"date":280,"type":21},"2027-11-16",{"name":282,"class":74},"The Foundation for Orthopaedics and Regenerative Medicine",{"id":284,"slug":285,"hasResults":11,"nctId":286,"briefTitle":287,"officialTitle":288,"acronym":4,"eligibilityCriteria":289,"healthyVolunteers":135,"sex":290,"minAge":17,"maxAge":108,"enrollmentInfo":291,"targetDuration":4,"studyType":58,"phases":293,"briefSummary":294,"conditions":295,"keywords":296,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":150,"lastUpdatePostDateStruct":307,"startDateStruct":309,"completionDateStruct":310,"leadSponsor":312,"locationsCount":75},"100528049","exogenous-ketone-supplementation-in-females-with-polycystic-ovary-syndrome-100528049","NCT06155708","Exogenous Ketone Supplementation in Females with Polycystic Ovary Syndrome","Exogenous Ketone Supplementation to Improve Cardiovascular Disease Risk Factors in Females with Polycystic Ovary Syndrome","Inclusion Criteria:\n\n* All female participants will report female sex assigned at birth\n* All participants will be aged 18 to 40\n* PCOS diagnosis\n\nExclusion Criteria:\n\n* Current smokers or a prolonged history of smoking\n* Presence or history of overt cardiometabolic disease (e.g., stage 2 hypertension, diabetes, heart disease), neurologic disease, or endocrinopathy (with the exception of PCOS)\n* Current pregnancy or currently breastfeeding\n* Current use of medications which may affect our outcomes of interest (e.g., anti-hypertensives, anti-androgens, metformin)","ALL",{"count":292,"type":21},60,[112],"Polycystic ovary syndrome (PCOS) affects 1 in 5 females of reproductive age. Commonly characterized as a disorder of infertility, PCOS is often accompanied by 3 potent cardiovascular disease (CVD) risk factors: insulin resistance, endothelial dysfunction, and elevated blood pressure. Accordingly, PCOS is associated with the development of CVD, the second leading cause of death in females in Canada. However, effective treatments to improve cardiovascular health in PCOS are lacking.\n\nExogenous ketone monoester (KME) ingestion has been shown to improves outcomes associated with insulin resistance, endothelial function, and blood pressure regulation in healthy individuals and individuals predisposed to CVD. Therefore, oral ketone supplements offer a practical and effective strategy for improving cardiovascular health; however, this treatment has yet to be evaluated in PCOS.\n\nTherefore, the overall goal of this project is to employ KME ingestion to improve markers of cardiovascular health in females with PCOS.\n\nOn two different days, participants will consume either a beverage containing a ketone supplement or a beverage containing a placebo supplement. The objectives are to compare responses between KME and placebo ingestion, and examine all outcomes related to cardiovascular health in females with PCOS in comparison with female controls of similar age and body mass index. The effects of KME ingestion will be quantified on: 1) glycemic control during an oral glucose tolerance test; 2) endothelial function using the flow-mediated dilation test; 3) blood pressure and acute blood pressure regulation; and 4) hemodynamic responses to acute exercise.",[27],[297,298,299,300,301,302,303,304,305,306],"Polycystic ovary syndrome","Ketone monoester ingestion","Insulin resistance","Endothelial function","Blood pressure","Oral glucose tolerance test","Flow mediated dilation","Handgrip exercise","Neurovascular transduction","Cold pressor test",{"date":308,"type":40},"2025-01-22",{"date":150,"type":21},{"date":311,"type":21},"2027-12",{"name":313,"class":74},"McGill University",{"id":315,"slug":316,"hasResults":11,"nctId":317,"briefTitle":318,"officialTitle":318,"acronym":4,"eligibilityCriteria":319,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":320,"enrollmentInfo":321,"targetDuration":4,"studyType":58,"phases":322,"briefSummary":323,"conditions":324,"keywords":334,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":335,"lastUpdatePostDateStruct":336,"startDateStruct":338,"completionDateStruct":340,"leadSponsor":342,"locationsCount":75},"100564741","in-vitro-maturation-of-human-eggs-100564741","NCT06633120","In Vitro Maturation of Human Eggs","Inclusion Criteria:\n\n* Infertile women diagnosed with PCOS or polycystic ovaries, or infertile women with good ovarian reserve\n* Antral follicle count (AFC) greater than 24\n* AMH greater than 3.5 ng\u002Fml\n* Body Mass Index less than 35\n* Accept to have embryos biopsied for PGT\n* Intend to perform embryo transfer within 4 months after completing the IVM cycle\n* Paternal (or donor) age \\<45, ejaculated sperm collection only (partner frozen and donor sperm acceptable), sperm morphology (strict criteria) \\>1%, motility \\> 20% and sperm count \\> 10 million per ml (so samples can be prepared through standard procedure)\n\nExclusion Criteria:\n\n* More than 2 failed IVF cycles","38 Years",{"count":57,"type":21},[112],"CCRM Fertility, a global pioneer in fertility treatment, research and science, is seeking participants for a new study on in vitro maturation (IVM). IVM requires less hormones to stimulate the ovaries than IVF, making it more affordable than IVF with fewer side effects. Participants that qualify for the study will receive a free cycle of IVM treatment at CCRM Fertility and including a new patient consultation, fertility testing, preimplantation genetic testing for aneuploidies (PGT-A), anesthesia and some medication",[325,27,28,326,244,327,328,329,330,331,332,333],"Healthy","Ovarian Reserve","Infertility Female","Infertility of Tubal Origin","Infertility Poly Cystic Ovary","AMH","In Vitro Maturation","IVM","IVF",[332,244,27,333],"2024-10-07",{"date":337,"type":40},"2024-10-09",{"date":339,"type":40},"2023-02-03",{"date":341,"type":21},"2030-08-30",{"name":343,"class":74},"Colorado Center for Reproductive Medicine",{"id":345,"slug":346,"hasResults":11,"nctId":347,"briefTitle":348,"officialTitle":349,"acronym":4,"eligibilityCriteria":350,"healthyVolunteers":11,"sex":16,"minAge":351,"maxAge":108,"enrollmentInfo":352,"targetDuration":4,"studyType":58,"phases":354,"briefSummary":355,"conditions":356,"keywords":4,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":358,"lastUpdatePostDateStruct":359,"startDateStruct":361,"completionDateStruct":363,"leadSponsor":365,"locationsCount":99},"100561515","lifestyle-changes-in-pcos-with-osa-and-nafld-100561515","NCT06591169","Lifestyle Changes in PCOS with OSA and NAFLD","Polycystic Ovarian Syndrome Women with NAFLD and Obstructive Sleeping Apnea: Program of Lifestyle Changes","Inclusion Criteria:\n\n* forty women\n* women complaint PCOS\n* women complain obstructive sleep apnea\n* women are obese\n* women complain fatty liver\n\nExclusion Criteria:\n\n* cardiac insult\n* renal insult\n* malignacy\n* pregnancy","30 Years",{"count":353,"type":21},40,[112],"Complain of obstructive sleeping apnea and fatty liver is common in PCOS women so lifestyle changes are recommended",[27,63,357],"OSA","2024-09-09",{"date":360,"type":40},"2024-09-19",{"date":362,"type":40},"2024-07-05",{"date":364,"type":21},"2024-12-15",{"name":366,"class":74},"Cairo University",{"id":368,"slug":369,"hasResults":11,"nctId":370,"briefTitle":371,"officialTitle":372,"acronym":4,"eligibilityCriteria":373,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":163,"enrollmentInfo":374,"targetDuration":4,"studyType":58,"phases":376,"briefSummary":377,"conditions":378,"keywords":379,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":384,"lastUpdatePostDateStruct":385,"startDateStruct":387,"completionDateStruct":389,"leadSponsor":391,"locationsCount":75},"100551553","effects-of-sprint-interval-training-versus-arabic-exercises-bmi-100551553","NCT06461585","Effects of Sprint Interval Training Versus Arabic Exercises BMI","Effects of Sprint Interval Training Versus Arabic Exercises BMI Waist-to-hip Ratio and Quality of Life in Obese Women PCOS","Inclusion Criteria:\n\nDiagnosed PCOS\n\n* Age: 18 - 35 years.\n* BMI ≥25 kg\u002Fm2\n* Unmarried females (5)\n* Oligomenorrhea\n* Irregular cycles (Have less than 9 periods in 1 year\n\nExclusion Criteria:\n\n* Congenital adrenal hyperplasia, androgen-secreting tumors, and Cushing's syndrome\n* Cardiovascular diseases and thrombotic diseases.\n* Systemic illness (Acute or chronic hepatitis or nephritis, musculoskeletal and pulmonary disorder)\n* Taking medications known to affect ovarian function within the past 3 months.\n* Patients suffer from mental problems.",{"count":375,"type":21},36,[112],"Polycystic ovary syndrome (PCOS) is the most common endocrine disorder in women of reproductive age and is the leading cause of infertility and anovulation. According to the Rotterdam criteria, the prevalence of PCOS is estimated to affect up to 20% of the female population. PCOS is characterized by increased androgen production and decreased ovulation leading to clinical manifestations including acne, hirsutism, male pattern baldness, irregular menstrual cycles, and infertility. In addition to concerns about fertility and hyperandrogenism, PCOS is considered a metabolic disorder, with an increased risk of developing insulin resistance (IR), hyperinsulinemia, dyslipidemia, and low-grade inflammation. In addition to genetic involvement, environmental aspects such as obesity conditions. affect the progression of PCOS or even make patients' clinical conditions worse. Exercise is an important component of PCOS management, and exercises have been shown to improve metabolic and reproductive outcomes in women with PCOS. The study will be a randomized clinical trial. This study will be completed in a time duration of 7 months after the approval of the synopsis. Sample size 32 is calculated by the Epi tool.variable for the sample size is BMI. By the non-probability convenience sampling technique, participants will be divided into 2 groups. Group A the Interventional group will receive SIT and Group B will receive the aerobic exercise. Group A will perform SIT 3 times a week for 30-second sprints on a cycle ergometer with 4 minutes of rest between each sprint, complete session will be for 30 -40 minutes while Group B will perform the aerobic exercise for 30-40 minutes of moderate-intensity continuous exercise on a treadmill and stationary cycle. The outcome measure will be evaluated by using the BMI Calculator, PCOSQOL, measuring tape Borg scale. After Collecting data from the before and after treatment sessions. The data will be analyzed by using SPSS version 25.",[27],[380,381,382,383],"BMI","High intensity interval training","PCOS Syndrome","Quality of life","2024-06-11",{"date":386,"type":40},"2024-06-17",{"date":388,"type":40},"2023-12-10",{"date":390,"type":21},"2024-07-10",{"name":392,"class":74},"Riphah International University",{"id":394,"slug":395,"hasResults":11,"nctId":396,"briefTitle":397,"officialTitle":398,"acronym":399,"eligibilityCriteria":400,"healthyVolunteers":135,"sex":290,"minAge":4,"maxAge":17,"enrollmentInfo":401,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":403,"conditions":404,"keywords":410,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":412,"lastUpdatePostDateStruct":413,"startDateStruct":415,"completionDateStruct":417,"leadSponsor":419,"locationsCount":75},"100342698","offspring-born-to-mothers-with-polycystic-ovary-syndrome-in-guangzhou-cohort-study-100342698","NCT03742011","Offspring Born to Mothers With Polycystic Ovary Syndrome in Guangzhou Cohort Study","Health of Offspring Born to Mothers With Polycystic Ovary Syndrome in Guangzhou Cohort Study","PCOS-BIG","Inclusion Criteria:\n\n* Offspring born to women diagnosed with PCOS\n* Offspring born to women with \\\u003C20 weeks of gestation, intended to eventually deliver in Guangzhou Women and Children's Medical Center\n* Permanent residents or families intended to remain in Guangzhou for ≥3 years\n\nExclusion Criteria:\n\n* None",{"count":402,"type":21},2000,"The Offspring Born to Mothers with Polycystic Ovary Syndrome in Guangzhou Cohort study (PCOS-BIG) was established to investigate the short- and long-term effects of intrauterine exposure to maternal PCOS on the health of offspring in Guangzhou, China. Data are collected regarding maternal PCOS subtypes, nursing, diet and education as well as health outcomes in their later life. Biological samples including blood and tissue samples are also collected from participants.",[27,405,219,406,407,408,409],"Offspring, Adult","Epigenetics","Insulin Resistance","Endocrine Disorder","Metabolic Disturbance",[27,219,406,411],"Glucolipid metabolism disorder","2024-02-22",{"date":414,"type":40},"2024-02-26",{"date":416,"type":40},"2012-02-01",{"date":418,"type":21},"2038-12-31",{"name":420,"class":74},"Guangzhou Women and Children's Medical Center"]